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Objectives This study sought to compare clinical, echocardiographic, and cardiopulmonary exercise testing response to cardiac
resynchronization therapy (CRT) in patients with unfavorable anatomy of coronary sinus (CS) veins, randomized to
transvenous versus surgical left ventricular (LV) lead implantation.
Background CRT efficacy depends on proper positioning of the LV lead over the posterolateral wall. A detailed pre-operative knowl-
edge of CS anatomy might be of pivotal importance to accomplish a proper LV lead placement over this area.
Methods Study population included 40 patients (age 66  4 years) with heart failure and indication to CRT, with unsuitable CS
branches anatomy documented by pre-operative multislice computed cardiac tomography; 20 patients (Group 1) un-
derwent surgical minithoracotomic LV lead implantation whereas 20 (Group 2) were implanted transvenously. New
York Heart Association functional class, echocardiographic, and cardiopulmonary exercise testing data were assessed
before and 1 year after CRT-system implant.
Results In all Group 1 patients, the LV leads were placed over the middle-basal segments of the posterolateral wall of the LV.
This was not possible in Group 2 patients. One year after CRT, in Group 1, a significant improvement of New York
Heart Association functional class, LV ejection fraction (from 28.8  9.2% to 33.9  7.2%, p  0.01), LV end-systolic
volume (from 165  53 ml to 134  48 ml, p  0.001), and peak VO2/kg (from 10.4  4.5 ml/kg/min to 13.1 
3.1 ml/kg/min, p  0.02) was observed. However, no improvement was observed in Group 2: LV ejection fraction
varied from 27.4  4.8% to 27.4  5.7% (p  0.9), LV end-systolic volume from 175  46 ml to 166  44 ml (p 
0.15), and peak VO2/kg from 11.2  3.2 ml/kg/min to 11.3  3.4 ml/kg/min (p  0.9). Changes after CRT between
groups were highly significant.
Conclusions In the setting of unfavorable CS branches of anatomy, CRT by a surgical minithoracotomic approach is preferable to
transvenous lead implantation. (J Am Coll Cardiol 2011;58:483–90) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.065Cardiac resynchronization therapy (CRT) represents a pri-
mary therapeutic option in the management of patients with
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2010, accepted February 8, 2011.advanced refractory heart failure (HF), an ejection fraction
0.35, and QRS duration of 120 ms. CRT has proven
effective in improving left ventricular (LV) systolic function,
exercise capacity, and myocardial oxygen consumption
(1–6) and in reducing LV volumes, HF-related hospital-
izations (7), and, primarily, mortality (7–9). Patients in
See page 491
whom LV lead position was retrospectively identified as
corresponding with the latest segment of mechanical acti-
vation have been revealed to have greater remodeling and
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Efficacy of Surgical Versus Endocardial LV Implant July 26, 2011:483–90improvement in outcome versus
patients in whom lead position
was not adequate (10–14). Al-
though large clinical trials have
shown high success rates for
transvenous LV lead implanta-
tion (from 88% to 95%), the
selective engagement of the cor-
onary sinus (CS) branch over the
obtuse marginal branch area,
which in most patients with left
bundle branch block represents
the region of highest intraven-
tricular electrical and mechanical
delay, is achieved in only 70% of
patients undergoing CRT proce-
dure. This can be due to the
absence of a suitable vein and/or
the presence of unfavorable vas-
cular patterns, as is the case of
tortuous, sharp, or angulated vessels. Failing to position the
LV catheter over the target area is considered the main
cause of inefficacy of CRT (8,9). In patients with unfavor-
able anatomy of CS main branches, the surgical direct
minithoracotomic intervention may represent an alternative,
viable strategy to implant the LV catheter over the postero-
lateral wall of the LV (15–17). Multislice computed tomog-
raphy (MSCT) is a new technique that allows an effective
visualization of the coronary venous system (18–20); this
imaging tool, when performed prior to the CRT procedure,
could be of great help in guiding the choice between
epicardial minithoracotomic and transvenous approaches.
The present prospective study was undertaken to assess the
clinical, echocardiographic, and cardiopulmonary exercise
testing (CPET) long-term response to CRT in patients
with pre-operative documentation of unfavorable CS main
veins anatomy, who underwent conventional transvenous or
minithoracotomic LV lead implantation.
Methods
The study population included 40 patients (mean age of
64.3 4.2 years) with HF and with unfavorable anatomy of
CS main veins, screened in our institution from June 2006
to April 2009 from a population of 215 patients with
indication to CRT, according to standard guidelines (21).
he unsuitability of CS main branches anatomy was docu-
ented by pre-operative MSCT, performed 1 to 2 days
efore the CRT system implant. All enrolled patients were
n sinus rhythm, had a mean LV ejection fraction of 28.1 
.3%, a left bundle branch block with QRS width of 164 
4 ms, and received an optimized therapy with angiotensin-
onverting enzyme inhibitors, beta-blockers, and diuretics.
pecific for this study, exclusion criteria were CS veins
natomy suitable for transvenous implantation with conven-
Abbreviations
and Acronyms
CPET  cardiopulmonary
exercise test
CRT  cardiac
resynchronization therapy
CS  coronary sinus
HF  heart failure
LV  left ventricle/left
ventricular
LVEF  left ventricular
ejection fraction
LVESV  left ventricular
end-systolic volume
MSCT  multislice
computed tomography
NYHA  New York Heart
Associationional tools, presence of atrial fibrillation, previously insertedardiac pacemakers, impaired renal function (creatinine
erum levels 2.0 mg/dl) and allergic reactions to contrast
gents (Fig. 1). Patients with irregular heart rate during
SCT or with inability to sustain a breath hold for 25 s and
ody mass index40 kg/m2 were also excluded. In no cases
as previous thoracotomy performed. Before CRT, in each
atient, New York Heart Association (NYHA) functional
lass, echocardiographic left ventricular end-systolic volume
LVESV), LVEF, and degree of mitral regurgitation (eval-
ated by Doppler imaging and graded on a 0 to 4 scale) were
ssessed. All patients were also evaluated by CPET; exercise
as done on a cyclo-ergometer (personalized ramp protocol,
reath-by-breath analysis) and measurements of peak oxy-
en consumption (peak VO2, ml/min), peak VO2/kg (ml/kg/
in), peak workload (WR, watts), and the slope of the
elationship between VE and CO2 (VE/VCO2) were ob-
ained from each patient.
Afterward, patients were prospectively randomized into 2
herapeutic arms: Group 1 (n  20) referred to epicardial
inithoracotomic with video-assisted thoracoscopy LV lead
mplantation; and Group 2 (n  20) in which LV lead
implantation was performed through a conventional trans-
venous endocardial approach.
At baseline, patients of both groups were similar with
respect to etiology of heart failure, NYHA class, echocar-
diographic data, and CPET parameters (Table 1). Moreover,
the use of HF medications (beta-blockers, angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
loop and potassium-sparing diuretics, nitrates and digoxin)
was not different in both groups of patients.
After device implantation, in all patients, pacing was
delivered in biventricular sequential mode. The atrioventric-
ular delay was optimized using Doppler echocardiography
by searching maximal transmitral diastolic filling without
premature termination of atrial filling. Patients of Groups 1
and 2 had an optimal mean sensed atrioventricular delay of
120  15 ms and 130  10 ms (p  0.07) with a mean
optimal paced atrioventricular delay of 132  18 ms and
Figure 1 Exclusion Criteria From the Study
PM-ICD  pacemaker implantable cardioverter-defibrillator.
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July 26, 2011:483–90 Efficacy of Surgical Versus Endocardial LV Implant125  15 ms (p  0.6). Right versus left ventricular pacing
elay was set at 0 in all patients. Approximately 12 months
fter implantation, NYHA functional class was re-evaluated
nd echocardiographic and CPET measures were repeated.
ll echocardiographic recordings were interpretable at base-
ine and during follow-up. Medical personnel unblinded
oward the study protocol performed CPET, echo, and
linical analysis during follow-up.
The study was approved and conducted in compliance
ith the regulation of the Institutional Ethic Committee.
ritten informed consent was obtained from all patients
fter careful explanation of the study protocol.
tudy design. This was a single-center, longitudinal, ran-
omized prospective study. Randomization was obtained by
computer-generated randomization list.
In this study, in each group of patients, the achievement
f successful positioning during CRT procedure of the LV
acing lead over the lateral or posterolateral wall of the LV
as evaluated. Clinical, echocardiographic, and CPET data
ere collected the week before CRT and after a mean
ollow-up period of 11.4  1.2 months. The primary
utcome of the study was the evaluation of an improvement
f NYHA class and echocardiographic and CPET param-
ters 1 year after CRT procedure in both groups of patients.
he secondary outcome was the reduction of HF-related
ospitalizations 1 year after CRT system implantation.
linical follow-up and drug regimen after CRT were
ptimized by the HF specialist in charge of the patient.
can protocol and image reconstruction. MSCT was
erformed by a multislice electrocardiogram-triggered sys-
em (Light Speed Pro, GE Medical Systems, Milwaukee,
isconsin); before scanning, care was taken to perform the
can at a sinus rate 65 beats/min, if necessary, by tempo-
Baseline ClinicalCharacteristics of the Study GroupsTable 1 Baseline ClinicalCharacteristics of the Study Groups
Group 1 Group 2 p Value
Male/female 17/3 16/4
Age, yrs 64.1 6 63 7.4 0.30
IDCM 16 15 0.56
ICMP 4 5 0.56
NYHA functional class
II 1 2 0.28*
III 11 13
IV 8 5
LVEF, % 28.8 9.2 27.4 4.8 0.7
LVESV, ml 165 53 175 46 0.06
Peak VO2/kg, ml/kg/min 10.4 5.0 11.2 3.2 0.07
QRS duration 160 28 167 22 0.6
IDCM patients 161 23 168 24 0.06
ICMP patients 157 24 167 19 0.08
*Chi-square test for trend.
ICMP  ischemic cardiomyopathy; IDCM  idiopathic dilated cardiomyopathy; LVEF  left
ventricular ejection fraction; LVESV left ventricular end-systolic volume; NYHA New York Heart
ssociation; VO2  oxygen consumption.arily increasing the dosage of beta-blockers.MSCT data were acquired using TC 64 slices-scanner
ith 64 0.625 mm collimation and a gantry rotation time
f 350 ms. According to the “electrocardiogram-pulsing
echnique,” the tube current was modulated with a maxi-
um current of 600 mA during a period between 40% to
0% of the R-wave to R-wave interval and a reduction by
0% during the remaining cardiac cycle.
During the scan, a fixed dose (80 ml) of contrast agent
Iomeron 400 mg/ml, Bracco, Italy) was injected intrave-
ously at a rate of 5.0 ml/s followed by a saline solution (50
l at 5.0 ml/s). MSCT scan was acquired by fluoroscopic
olus tracking technique, during breath hold (about 10 s)
nd evaluated by 3 blinded expert readers with volume
endering reconstruction (CardioQ3 package GE Medical
ystems).
S anatomic findings. In the study population, MSCT
llowed the identification of the location of CS ostium in
elation to the right atrium and the evaluation of the
resence, number, location, and size of CS tributaries,
nalyzed on volume-rendered reconstructions. Finally, the
ourse, tortuosity, and angulation of CS veins in 3 orthog-
nal planes were also studied. In this study, we used highly
elective criteria to define unfavorable CS venous anatomy.
his lead to a high incidence rate (about 20% of all patients
mplanted in our institution) of CRT candidates in whom
he achievement of the positioning of the LV catheter over
he lateral or posterolateral wall through a transvenous
pproach was considered not feasible (22). Unfavorable
eins anatomy was defined if 1 of the following occurred:
) absence of a vein over the target area; 2) excessive
ortuosity of the vein; 3) take-off angle of the target branch
rom the CS60°; and 4) diameter of the target vein3 mm.
able 2 reports anatomically unsuitable CS vein patterns
nd final LV lead positions obtained in both groups of
atients.
urgical minithoracotomic technique with video-assisted
horacoscopy. The intervention was performed under gen-
ral anesthesia using a double lumen tube for unilateral lung
entilation. In right lateral decubitus position (30°/40°), a
Anatomic Patterns and Final LV Lead Positionin Both Groups of P tientsTable 2 Anatomic Patterns and Final LV Lead Positionin Both Groups of Patients
Group 1 Group 2
Unfavorable anatomy
Absence of lateral or posterolateral vein 2 3
Angle from CS 60° of lateral vein 4 4
Tortuosity of lateral vein 5 5
Diameter of lateral vein 3 mm 5 4
Diameter of posterolateral vein 3 mm 4 4
Final LV lead position
Basal-middle lateral wall 16 0
Middle posterolateral wall 4 0
Apical posterior vein 0 11
Proximal posterior vein 0 3
Great cardiac vein 0 6CS  coronary sinus; LV  left ventricular.
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Efficacy of Surgical Versus Endocardial LV Implant July 26, 2011:483–90lateral left minithoracotomy (3 cm) in fifth intercostal space
was made and a 5-mm camera port was inserted in the same
space. A pericardial 2-cm incision was made anteriorly to
the phrenic nerve. Once the lateral wall of the left ventricle
was exposed and the marginal arteries identified, a bipolar
epicardial screw-in lead (Myodex 1084T, St. Jude Medical,
Minneapolis, Minnesota) was inserted and placed over the
mid-basal segments of the posterolateral or lateral wall. The
implantation of the lead on LV surface was guided by
intraoperative electrophysiologic evaluation of the segment
with the highest degree of electrical intraventricular delay
and higher increase of systemic blood pressure during LV
pacing. In relation to the limited size of thoracotomy, the
regions tested by this method during operation were 3.0 
1.0. The mean electrical intraventricular delay recorded over
the tested lateral or posterolateral wall segments was 48 
14 ms, and the mean increase of blood pressure during LV
pacing was 34  11 mm Hg. After defining the optimal
pacing location, the LV lead was screwed in and then was
tunneled subcutaneously to the left subclavicular region to
the device pocket.
Chest tubes were removed after a mean of 22  6 h and
patients remained in the intensive care unit for less than
18 h; 48 h after operation, patients underwent endocardial
implantation of right atrial and right ventricular shocking
and pacing leads. There was neither significant morbidity
nor mortality related to the minithoracotomic procedure.
Seventeen patients of this group received a cardioverter-
defibrillator (Contak Renewal, Guidant, St. Paul, Minne-
sota; or Atlas HF, St. Jude Medical) and 3 a pacemaker
(Contak TR, Guidant).
Biventricular device transvenous implantation. In 18 of
20 patients who underwent transvenous procedure, a
cardioverter-defibrillator (Guidant Contak Renewal or St.
Jude Atlas HF) was implanted, whereas the remaining 2
received a pacemaker (Guidant Contak TR). The right
atrial and ventricular leads were positioned conventionally.
The LV pacing lead was inserted by left subclavian approach
and advanced through CS into a CS vein unrelated to the
mid-basal segments of the lateral or posterolateral wall.
Procedural Data in Groups 1 and 2Table 3 Procedural Data in Groups 1 and 2
Procedural Data
Mean procedure duration, min
Mean time to LV catheter positioning, min
Total fluoroscopic time, min
Acute pacing thresholds, V
Pacing impedance, Ohms
Sensing values, mV
12-month pacing thresholds, V
Post-operative stay, days
CS veins sampled during procedure
Regions tested during surgery
Mean electrical intraventricular delay, ms
Mean blood pressure increase during LV pacing, mm HgLV  left ventricular.Guided by a conventional retrograde CS angiography (that
confirmed MSCT pre-operative anatomic findings), the
physician who implanted the LV lead tried to achieve the
most satisfactory LV lead position by sampling different CS
veins (mean 3.5 1.5 veins). The purpose was to obtain the
shorter width of the QRS complex and the highest increase
in arterial systolic pressure with biventricular pacing.
Statistics. All continuous data were presented as mean 
D and categorical data as n (%). Within-group compari-
ons were performed by paired t test for continuous variables
nd by McNemar test for categorical variables. Distribution
f NYHA functional class was compared by using the
hi-square test for trend. Between-group comparisons were
erformed by computing pre/post variations and tested by
ovariance analysis adjusting for baseline values. All tests
ere 2-sided and p values 0.05 were considered signifi-
ant. All analyses were performed using SPSS (version 17,
PSS Inc., Chicago, Illinois). Finally, multivariate analysis
as been performed in all parameters for which changes
ere present (0.05) at univariate analysis 1 year after
RT; correction for multiple testing was performed by the
onferroni-Holm method.
esults
n all patients of Group 1, the pacing lead was positioned
ver the posterolateral wall of the LV. In 16 patients, the
V lead was positioned on the epicardium over the middle-
asal segments of the lateral wall, in the area of the obtuse
arginal branch of the circumflex artery, and in the remain-
ng 4 patients, the LV lead was implanted more posteriorly
ver the middle posterolateral wall of the LV (Table 2).
ean procedure duration (skin-to-skin) and total fluoro-
copic time were lower in Group 1 than in Group 2, mainly
n relation to the significantly lower time required for
picardial LV lead implantation as compared to the time
ecessary for endocardial positioning (Table 3). Acute
acing thresholds, impedance, and sensing values recorded
uring implantation did not significantly differ in surgical
nd transvenous groups; similarly, 12-month thresholds
Group 1 Group 2 p Value
128 36 188 45 0.03
13 8 34 17 0.02
22 8 54 22 0.03
1.1 0.6 1.4 0.7 0.07
938 46 1,135 78 0.8
14.4 6.7 12.2 5.3 0.7
1.3 0.5 1.5 0.7 0.5
10 3 7 3 0.04
3.5 1.5
3.0 1
48 14
34 11
oation th
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July 26, 2011:483–90 Efficacy of Surgical Versus Endocardial LV Implantwere not different in both groups. In 4 patients of the
surgical group, a pleural effusion, not requiring a specific
treatment, was recorded in the post-surgical period. A
dislodgment of the LV catheter requiring re-operation
occurred in 1 patient of Group 2. Post-operative hospital
stay was significantly longer in patients who underwent
surgical LV lead implantation (Table 3).
At the end of the follow-up period (12 months), in
Group 1, a significant improvement of NYHA class and of
LVEF and a decrease of LVESV and of mitral regurgitation
grade scale were recorded. Similarly, CRT allowed a marked
increase of peak VO2 and peak VO2/kg, whereas changes of
peak WR and VE/VCO2 slope showed a trend toward an
improvement but were not statistically different (Table 4).
Finally, in this group during follow-up, no death occurred
nor was cardiac transplantation necessary (Table 5).
In 11 patients who underwent a transvenous procedure,
guided by MSCT and perioperative CS angiographic find-
ings, the LV lead was implanted in the apical segments of a
posterior vein; in 3 patients, over a proximal posterior vein;
and in 6 patients, in the great cardiac vein (Table 2). In
patients of this group, 12 months after implantation,
NYHA functional class remained unchanged, as LVEF and
LVESV did not vary significantly. However, a slight but
significant improvement of mitral regurgitation grade scale
was recorded. Moreover, all CPET-derived parameters
NYHA, Echocardiographic, and Functional CPETTable 4 NYHA, Echocardiographic, and Func
Group 1
Pre-CRT Post-CRT
Clinical parameters
NYHA functional class I 0 2
NYHA functional class II 1 15
NYHA functional class III 11 3
NYHA functional class IV 8 0
Echocardiographic
parameters
LVEF, % 28.8 9.2 33.9 7
LVESV, ml 165 53 134 4
MI (1–4) scale 2.7 0.8 2.3 1
CPET parameters
Peak VO2, ml/min 824 445 1,043 3
Peak VO2/kg, ml/kg/min 10.4 4.5 13.1 3
Peak WR, W 58 38 71 2
VE/VCO2 35 9 33 6
Group 2 Post-CRT n  17. *McNemar test.
CPET  cardiopulmonary exercise test; CRT  cardiac resynchroniz
VE  ventilation; WR  work rate; other abbreviations as in Table 1.
Follow-Up Data in Both Groups of PatientsTable 5 Follow-Up Data in Both Groups of Patients
Follow-Up Data Group 1 Group 2
Months 11 3 12 2
Followed 1 yr 20/20 17/20
Died 0 2
Dropped out 0 0Cardiac transplantation 0 1were unchanged (Table 4). During the follow-up period, 2
patients of this group died (1 for worsening heart failure, 1
for untreatable arrhythmias) and 1 underwent urgent heart
transplantation (Table 5). Twelve months after implanta-
tion, at multivariate analysis, in surgical patients, the im-
provement of NYHA class, LVEF, LVESV, peak VO2, and
peak VO2/kg was significantly higher than in nonsurgical
nes; instead, changes of peak workload and of VE/VCO2
between the 2 groups were not significant (Table 6). Finally,
after 12 months of CRT, the HF-related hospitalizations
for each patient were significantly lower in Group 1 than in
Group 2 (1.5  0.5 vs. 4.7  1.2, p  0.003). Finally, after
CRT procedure in transvenous and surgical patients, the use
of beta-blockers, angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, loop and potassium-sparing
diuretics, nitrates, and digoxin was optimized by the HF
specialist, without significant differences between the 2
groups’ patients (Table 7).
Discussion
Our study shows that, in patients with an unfavorable CS
anatomy, a surgical strategy aimed at a selective lead
positioning over the middle-basal segments of the lateral or
the middle area of posterolateral wall of the LV is superior
to the transvenous placement in a second- or third-choice
segment guided by the local anatomy.
Even though the papers of Derval et al. (23) and Saxon et
al. (24) have indicated that the acute hemodynamic im-
provement after CRT is rarely related to lead placement
over the lateral wall of the LV. The majority of studies
(3,25–29) have underlined the pivotal importance of an
optimal LV lead positioning over the posterolateral or
lateral wall of the LV in determining a positive hemody-
ges in Groups 1 and 2l CPET Changes in Groups 1 and 2
p Value
Group 2
p ValuePre-CRT Post-CRT
0.0042* 0 0 0.9197*
2 5
13 11
5 1
0.01 27.4 4.8 27.4 5.7 0.98
0.001 175 46 166 44 0.15
0.008 2.7 1.2 2.4 1 0.01
0.03 855 331 880 309 0.69
0.02 11.2 3.2 11.3 3.4 0.90
0.10 56 26 65 27 0.26
0.26 37 8 35 9 0.57
erapy; MI  mitral insufficiency; VCO2  carbon-dioxide production;Chantiona
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Efficacy of Surgical Versus Endocardial LV Implant July 26, 2011:483–90early LV reverse remodeling. The hemodynamic improve-
ment obtained by pacing these areas, which, in almost all
HF patients with left bundle branch block, represent the
sites of latest mechanical activation (30–32), is greater than
that provided by stimulation within the great cardiac vein or
in the anterior venous branches of CS. That may even
worsen the hemodynamic profile because of early stimula-
tion of interventricular septum with further loss of LV
synchrony. In the study of Zhang et al. (33), the placement
of the LV lead at a posterolateral position was predictive of
a lower all-cause and cardiovascular mortality, providing
additional prognostic value to the presence and assessment
of dyssynchrony. In this article, the absence of dyssynchrony
and a nonposterolateral lead position were associated with
inadequate LV reverse remodeling response. Conversely,
the rate of responders to CRT increased from 60% in the
presence of dyssynchrony alone to 86% when dyssynchrony
and posterolateral LV lead position coexisted. However,
owing to technical limitations of trans-CS implantation of
the LV lead, in at least 30% of patients who underwent
CRT procedure, an adequate placement of the LV catheter
Long-Term Effects of CRT: Comparison BetweenTable 6 Long-Term Effects of CRT: Compari
Group 1
Clinical parameters
NYHA functional class I 2
NYHA functional class II 15
NYHA functional class III 3
NYHA functional class IV 0
Echocardiographic
parameters
LVEF, % 33.9 7.2 2
LVESV, ml 134 48 1
CPET parameters
Peak VO2, ml/min 1,043 307 8
Peak VO2/kg, ml/kg/min 13.1 3.1 1
Peak WR, W 71.7 27
VE/VCO2 33.6 6
Group 1, n  20; Group 2, n  17. *Chi-square test for trend. †Covar
performed by the Bonferroni-Holm method.
Abbreviations as in Tables 1 and 4.
Use of HF Medications Before and AfterCRT Procedure in Groups 1 and 2Table 7 Use of HF M dications Before and AfterCRT Procedure in Groups 1 and 2
HF Medications
Group 1 Group 1
Pre-CRT Post-CRT* Pre-CRT Post-CRT*
Carvedilol 14 14 13 13
Bisoprolol 6 5 7 7
ACE inhibitors 19 19 19 17
Furosemide 20 20 19 17
Spironolactone 18 16 17 17
Nitrates 12 10 11 10
Digoxin 8 6 7 6
Values are number of patients. *At long-term evaluation.a
ACE  angiotensin-converting enzyme; CRT  cardiac resynchronization therapy; HF  heart
failure.over the lateral wall of the LV may not be feasible, even by
experienced implanters. In this setting, as reported by
several investigators (34,35), usually the LV lead is im-
planted into an atypical site (i.e., anterior or middle cardiac
veins). Indeed, Alonso et al. (34) reported that 36% of LV
leads were atypically placed and, in a later experience (35),
nly a 70% rate of achievement of positioning of the LV
ead over the intended target site (lateral or posterolateral
ributaries of the CS) was described. In the EASYTRAK
egistry 2001 (36), in only 54% of patients, the lateral wall
as reached, and in more than 30% of recorded cases, the
S lead was implanted in an anterior position. In prevent-
ng the implantation of the LV catheter over a hemody-
amically ineffective area, the pre-operative study of the CS
ain veins anatomy might be of primary importance to
dentify unsuitable anatomic patterns, leading us to prefer
he minithoracotomic approach to achieve an effective LV
ead positioning. The feasibility of the surgical approach was
emonstrated in the study of Mair et al. (15) in which a
orrect lead positioning over the obtuse marginal branch
rea was achieved in all surgical patients in comparison to
nly 70% of patients who underwent conventional CS-lead
mplantation. The safety of the minithoracotomic and
ndoscopic (video-assisted thoracoscopy surgery or robotic)
pproaches for LV lead implantation has been previously
hown by Navia et al. (16) and Gabor et al. (17). These
nvestigators reported the important advantage of the sur-
ical approach, which enables the direct visualization of the
ateral LV wall, allowing physicians to avoid the areas of
carred myocardium that might be associated with exces-
ively high pacing thresholds and/or ineffective pacing.
oreover, the surgical procedure provides the opportunity
f a more appropriate selection of pacing site in the lateral
all, by performing an electrophysiologic and hemodynamic
apping, guiding the surgeon to the area of latest electrical
ps 1 and 2etween Groups 1 and 2
2 p Value p Value† p Value‡
0.0007*
5.7 0.008 0.01
44 0.03 0.04
309 0.04 0.05
3.4 0.03 0.04
27 0.54 0.99
9 0.43 0.96
nalysis adjusting for baseline values. ‡Correction for multiple testingGrouson B
Group
0
5
11
1
7.4
64
80
1.3
65
35
iance activation and best hemodynamic response.
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July 26, 2011:483–90 Efficacy of Surgical Versus Endocardial LV ImplantThe current study is the first in which long-term clinical,
echocardiographic, and CPET changes after CRT have
been evaluated in a selected population of candidates to
CRT with pre-operative documentation of unsuitable anat-
omy of CS main branches, randomized to transvenous
procedure versus surgical LV lead implantation. The first
finding from this study was that, in all patients referred to
surgical minithoracotomic implantation and in no patients
of the transvenous group, the LV lead was placed over the
posterolateral wall of the LV. In the surgical group, but not
in transvenously implanted patients, 12 months after start-
ing CRT, a significant increase with respect to baseline, of
NYHA class, LVEF, peak VO2 and peak VO2/kg were
ecorded; a marked decrease of LVESV was also recorded.
oreover, the comparative analysis of data recorded in both
roups of patients at the end of the follow-up period showed
hat the improvement of NYHA class, LVESV, LVEF, and
PET parameters was significantly higher in surgically
reated patients than in patients who underwent conven-
ional transvenous procedure. Two are the major prognostic
ndicators independent of each other, obtained by CPET,
eak VO2 and VE/VCO2 slope. In Group 1, the former
mproved and the latter did not, whereas both remained
nchanged in Group 2. This is likely due to the close
elationship between cardiac output and VO2, whereas the
VE/VCO2 is influenced by ventilation/perfusion matching in
he lung and ventilation reflex regulation. Therefore, it is
nlikely that CRT influences the VE/VCO2 slope except after
prolonged and marked improvement of clinical conditions.
Study limitations. First, we studied a small number of
patients with a 1-year follow-up. So larger and more
prolonged studies are certainly advocated to confirm our
findings before a large-scale utilization of surgical LV lead
positioning can be proposed in patients with unfavorable
cardiac veins anatomy. Second, the patient population of
our study was highly selected (patients with previous pace-
maker, impaired renal function, irregular heart rate during
MSCT, inability to sustain a breath hold for 25 s, and body
mass index 40 kg/m2) and this could limit the approach
onsisting of pre-operative evaluation of CS anatomy by
SCT followed by surgical LV lead implantation to a
ider population of CRT procedure candidates. Third, the
efinition of “unfavorable cardiac veins anatomy” is subjec-
ive and, at present, a quantitative scale of favorableness of
ardiac veins anatomy is lacking; moreover, the technical
ifficulties related to an unfavorable CS anatomy, leading to
surgical procedure, could in some cases be overcome by an
xperienced implanter with modern tools. Therefore, the
esults of our study are limited to patients with a clearly
nfavorable anatomy. Fourth, we also recognized that in
atients undergoing to the surgical procedure, it was possi-
le to guide, by intraoperative electrophysiologic and hemo-
ynamic evaluation, the surgeon allowing him to reach the
egment of the highest degree of electrical intraventricular
elay and higher increase of systemic blood pressure during
V pacing. So it was not just a simple surgical leadositioning on LV free wall but an electrophysiologically
nd hemodynamically guided lead positioning. Finally, we
xcluded patients with previous thoracotomy, which might
ncrease the surgical risk of LV lead implantation during a
ollowing thoracotomy as well as might impede a proper
ead positioning. Consequently, our results should not be
pplied to HF patients with previous thoracotomy.
onclusions
ata from this study underline the importance of the
re-operative knowledge, gained in the present study by
SCT, of CS main branches anatomy, because it allows the
creening of patients with unfavorable anatomic patterns. In
hese patients, an accurate electrophysiologically and hemo-
ynamically guided LV lead positioning over the postero-
ateral wall of the LV by the minithoracotomic surgical
pproach is preferable. The improvement of clinical, echo-
ardiographic, and CPET parameters recorded in surgical
atients as compared in patients in whom the lead was
laced into another nonposterolateral vein, suggests that
hysicians should consider the epicardial implantation as
he first line approach in patients with unfavorable CS
natomy.
Reprint requests and correspondence: Prof. Piergiuseppe Agos-
toni Centro Cardiologico Monzino, IRCCS, Via Parea 4, 20138
Milan, Italy. E-mail: piergiuseppe.agostoni@unimi.it.
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